Saturday 17 October 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 14.3%, free cash flow grew 74.2% and total debt rose 1.43%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
7.08
0.52
−6.84%
Follow TKNO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.97 | 3.71 | 5.02 | 8.32 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(646.81) | (46.12) | (439.90) | (167.31) | |
P/B ratio |
4.87 | 2.39 | 2.96 | 4.56 | |
Price to Tangible BV |
5.95 | 2.91 | 3.58 | 5.48 | |
EV/Sales |
6.97 | 3.69 | 4.91 | 8.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(48.54) | (19.53) | (23.02) | (35.78) | |
EV/FCF |
(41.41) | (17.03) | (20.33) | (31.11) | |
Quick Ratio |
3.32 | 3.40 | 3.44 | 3.93 | |
Current Ratio |
4.49 | 4.59 | 4.58 | 5.27 | |
Net Debt/EBITDA |
3.31 | 1.65 | 2.69 | 3.48 | |
Debt/Assets |
13.79% | 13.35% | 12.67% | 12.15% | |
Debt/Equity |
0.21 | 0.20 | 0.19 | 0.18 | |
Asset Turnover |
0.42 | 0.39 | 0.36 | 0.34 | |
Operating CF/Net income |
0.15 | 0.74 | 0.10 | 0.46 | |
Capex/Depreciation |
(0.08) | (0.15) | (0.22) | (0.27) | |
Interest Coverage |
(11.47) | (19.63) | (21.84) | (21.14) | |
Research and Development Expense of Revenue |
4.55% | 5.50% | 5.23% | 5.18% | |
Selling, General and Administrative Expense of Revenue |
56.91% | 64.87% | 70.55% | 61.16% | |
Intangible Assets out of Total Assets |
0.12 | 0.12 | 0.12 | 0.11 | |
Share Based Compensation of Revenue |
5.10% | 6.27% | 7.78% | 8.13% | |
Graham Net Nets |
(0.01) | (0.01) | 0.00 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.46%) | (11.07%) | (8.68%) | (5.65%) | |
Free Cash Flow Yield |
(2.41%) | (5.85%) | (4.82%) | (3.17%) | |
Revenue per Share |
0.23 | 0.21 | 0.19 | 0.20 | |
Operating CF per Share |
(0.01) | (0.06) | (0.01) | (0.04) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.01) | (0.07) | (0.02) | (0.04) | |
Cash per Share |
0.33 | 0.33 | 0.40 | 0.41 | |
Shareholders Equity per Share |
1.17 | 1.21 | 1.29 | 1.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.17 | 1.21 | 1.29 | 1.36 | |
Free Cash Flow |
(0.60) | (3.58) | (0.81) | (2.37) | |
Working Capital |
23.95 | 24.78 | 26.97 | 29.63 | |
Capital Expenditures |
(0.12) | (0.22) | (0.35) | (0.39) | |
Net Current Asset Value |
(2.45) | (2.06) | (0.30) | 1.59 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.03 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.27 | 5.64 | 4.47 | 4.87 | |
Average Payables |
1.32 | 1.59 | 1.10 | 1.03 | |
Average Inventory |
7.26 | 6.72 | 6.93 | 7.29 | |
Average Assets |
103.18 | 106.33 | 111.18 | 115.86 | |
Average Common Equity |
69.33 | 71.76 | 75.58 | 79.96 |
Columns are period end dates